LXRX Q1 2022 Earnings — Lexicon Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

LXRXLexicon Pharmaceuticals, Inc.

$704M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$37,000+37.0% YoY

Gross Profit

-$72,000-194.6% margin

Operating Income

-$23M-63189.2% margin

Net Income

-$23M-63448.6% margin

EPS (Diluted)

$-0.16

QoQ Revenue Growth

+164.3%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$136M

Total Liabilities

$43M

Stockholders' Equity

$93M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37,000	$27,000	+37.0%
Gross Profit	-$72,000	-$13M	+99.4%
Operating Income	-$23M	-$21M	-12.2%
Net Income	-$23M	-$21M	-12.0%